• Publications
  • Influence
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated. Expand
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures. Expand
Vertebral fracture assessment using a semiquantitative technique
The semiquantitative approach can be applied reliably in vertebral fracture assessment when performed using well‐defined criteria, and this approach was compared with a quantitative morpho‐metric approach. Expand
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
This newer evidence suggests that AFFs are stress or insufficiency fractures, and studies with radiographic review consistently report significant associations between A FFs and BP use, although the strength and magnitude of effect vary. Expand
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures. Expand
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
  • E. Shane, D. Burr, +24 authors M. Whyte
  • Medicine, Biology
  • Journal of bone and mineral research : the…
  • 1 November 2010
Given the relative rarity of atypical femoral fractures, the task force recommends that specific diagnostic and procedural codes be created and that an international registry be established to facilitate studies of the clinical and genetic risk factors and optimal surgical and medical management of these fractures. Expand
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT)
The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis. Expand
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial
It is indicated that raloxifene treatment over 3 years not only preserves bone mass but also lowers the risk of new vertebral fractures in postmenopausal women with osteoporosis, regardless of whether they have had fractures before starting treatment. Expand
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation
In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture and was associated with a lower incidence of breast cancer. Expand
Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure
Histomorphometry and μCT of 51 paired iliac crest biopsy specimens from women treated with teriparatide revealed significant increases in cancellous bone volume, cancellous bone connectivity density,Expand